KIR6.2 Antibody (B-9): sc-390104

KIR6.2 Antibody (B-9) is a mouse monoclonal IgG2a antibody that detects KIR6.2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Anti-KIR6.2 antibody (B-9) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. KIR6.2 protein functions as a critical component of ATP-sensitive potassium channels, linking cellular metabolism to electrical activity. ATP-sensitive potassium channels primarily reside in pancreatic beta cell plasma membranes, regulating insulin secretion in response to glucose levels. Mutations in KIR6.2-encoding genes can lead to disorders with unregulated insulin release, contributing to conditions like congenital hyperinsulinism. KIR6.2 protein forms a hetero-octameric complex with sulfonylurea receptor (SUR), and interaction between these subunits enables channel activity and regulation. KIR6.2 intracellular domains participate in channel gating mechanisms, proving significant for understanding physiological and pathophysiological roles in various tissues.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

KIR6.2 Antibody (B-9) References:

1. ATP-sensitive potassium channels: structures, functions, and pathophysiology.  |  Inagaki, N. and Seino, S. 1998. Jpn J Physiol. 48: 397-412. PMID: 10021494
2. ATP-sensitive potassium channels: a model of heteromultimeric potassium channel/receptor assemblies.  |  Seino, S. 1999. Annu Rev Physiol. 61: 337-62. PMID: 10099692
3. The structure and function of the ATP-sensitive K+ channel in insulin-secreting pancreatic beta-cells.  |  Miki, T., et al. 1999. J Mol Endocrinol. 22: 113-23. PMID: 10194514
4. Congenital hyperinsulinism: molecular basis of a heterogeneous disease.  |  Meissner, T., et al. 1999. Hum Mutat. 13: 351-61. PMID: 10338089
5. Mapping of the physical interaction between the intracellular domains of an inwardly rectifying potassium channel, Kir6.2.  |  Tucker, SJ. and Ashcroft, FM. 1999. J Biol Chem. 274: 33393-7. PMID: 10559219
6. Simulating PIP2-Induced Gating Transitions in Kir6.2 Channels.  |  Bründl, M., et al. 2021. Front Mol Biosci. 8: 711975. PMID: 34447786
7. Kir6.2 is essential to maintain neurite features by modulating PM20D1-reduced mitochondrial ATP generation.  |  Song, N., et al. 2021. Redox Biol. 47: 102168. PMID: 34673451
8. Kir6.2-deficient mice develop somatosensory dysfunction and axonal loss in the peripheral nerves.  |  Nakai-Shimoda, H., et al. 2022. iScience. 25: 103609. PMID: 35005553
9. Structure of an open KATP channel reveals tandem PIP2 binding sites mediating the Kir6.2 and SUR1 regulatory interface.  |  Driggers, CM., et al. 2024. Nat Commun. 15: 2502. PMID: 38509107
10. Molecular Dynamics Simulation of Kir6.2 Variants Reveals Potential Association with Diabetes Mellitus.  |  Elangeeb, ME., et al. 2024. Molecules. 29: PMID: 38675722
11. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor.  |  Inagaki, N., et al. 1995. Science. 270: 1166-70. PMID: 7502040
12. Inwardly rectifying potassium channels: their molecular heterogeneity and function.  |  Isomoto, S., et al. 1997. Jpn J Physiol. 47: 11-39. PMID: 9159640

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-KIR6.2 Antibody (B-9) has 12 citations in a variety of scientific publications.

Primary antibodies like Anti-KIR6.2 Antibody (B-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

KIR6.2 Antibody (B-9) Specifications

Alternate Product Name: KIR6.2

Product Clone Name: B-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a lambda light chain

Amino Acids: 301-337

Epitope Target: KIR6.2

Epitope Species: human

Product Reactivity/Detection: KIR6.2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine and avian

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a lambda light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 12 citations in various scientific publications

Available Conjugates/Forms for KIR6.2 Antibody (B-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin